p53 Expression Is a Strong Marker of Inferior Survival in De Novo Diffuse Large B-Cell Lymphoma and May Have Enhanced Negative Effect With MYC Coexpression | Zendy

Yi Xie | Zendy; Mohmad Ajaz Bulbul | Zendy; Lingyun Ji | Zendy; Casey M. Inouye | Zendy; Susan Groshen | Zendy; Anil Tulpule | Zendy; Dennis P. O’Malley | Zendy; Endi Wang | Zendy; Imran Siddiqi | Zendy

Open Access

p53 Expression Is a Strong Marker of Inferior Survival in De Novo Diffuse Large B-Cell Lymphoma and May Have Enhanced Negative Effect With MYC Coexpression

Author(s) -

Yi Xie,

Mohmad Ajaz Bulbul,

Lingyun Ji,

Casey M. Inouye,

Susan Groshen,

Anil Tulpule,

Dennis P. O’Malley,

Endi Wang,

Imran Siddiqi

Publication year - 2014

Publication title -

american journal of clinical pathology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.859

H-Index - 128

eISSN - 1943-7722

pISSN - 0002-9173

DOI - 10.1309/ajcpphmz6vhf0wqv

Subject(s) - international prognostic index , lymphoma , diffuse large b cell lymphoma , immunohistochemistry , germinal center , phenotype , univariate analysis , cancer research , rituximab , pathology , medicine , oncology , biology , b cell , multivariate analysis , immunology , gene , antibody , biochemistry

To examine interactions among clinical factors and pathologic biomarkers in predicting the outcome of patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab-based immunochemotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research